Nuragalin D 50/20 Capsule contains a combination of Pregabalin 50 mg and Duloxetine 20 mg, formulated to manage neuropathic pain and associated depressive symptoms. Pregabalin, an anticonvulsant and analgesic agent, modulates calcium channels in the central nervous system, reducing neurotransmitter release and alleviating neuropathic pain. Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), enhances the levels of these neurotransmitters in the synaptic cleft, contributing to pain relief and improving mood disorders such as depression and anxiety. This combination is particularly effective in patients with chronic neuropathic pain conditions, including diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia, where pain is often accompanied by psychological distress. Nuragalin D 50/20 Capsule should be administered as prescribed by a healthcare professional, with dosage adjustments based on therapeutic response and tolerability. Common adverse effects may include dizziness, somnolence, dry mouth, nausea, and fatigue; patients should be monitored for any signs of hypersensitivity or worsening mood symptoms. Caution is advised in patients with hepatic or renal impairment, and abrupt discontinuation should be avoided to prevent withdrawal symptoms. This combination therapy offers a synergistic approach to managing complex pain syndromes with comorbid mood disorders.